Details for Patent: 10,131,667
✉ Email this page to a colleague
Which drugs does patent 10,131,667 protect, and when does it expire?
Patent 10,131,667 protects PEMAZYRE and is included in one NDA.
This patent has one hundred and thirteen patent family members in thirty-seven countries.
Summary for Patent: 10,131,667
| Title: | Substituted tricyclic compounds as FGFR inhibitors |
| Abstract: | The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer. |
| Inventor(s): | Wu; Liangxing (Wilmington, DE), Zhang; Colin (Berwyn, PA), He; Chunhong (Chadds Ford, PA), Lu; Liang (Hockessin, DE), Yao; Wenqing (Chadds Ford, PA) |
| Assignee: | Incyte Corporation (Wilmington, DE) |
| Application Number: | 15/408,768 |
|
Patent Claim Types: see list of patent claims | Use; |
More… ↓ |
Drugs Protected by US Patent 10,131,667
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-001 | Apr 17, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT | ⤷ Subscribe | ||||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-002 | Apr 17, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT | ⤷ Subscribe | ||||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-003 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,131,667
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2861595 | ⤷ Subscribe | PA2021519 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2861595 | ⤷ Subscribe | 301131 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2861595 | ⤷ Subscribe | LUC00222 | Luxembourg | ⤷ Subscribe |
| European Patent Office | 2861595 | ⤷ Subscribe | CA 2021 00033 | Denmark | ⤷ Subscribe |
| European Patent Office | 2861595 | ⤷ Subscribe | 122021000054 | Germany | ⤷ Subscribe |
| European Patent Office | 2861595 | ⤷ Subscribe | 2021C/536 | Belgium | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
